



Published in final edited form as:

*Pediatr Res.* 2019 August ; 86(2): 261–268. doi:10.1038/s41390-019-0379-7.

## Comparison of fetal growth by maternal prenatal acetaminophen use

Melissa M. Smarr<sup>1,2,\*</sup>, Joe Bible<sup>3</sup>, Nicole Gerlanc<sup>4</sup>, Germaine M. Buck Louis<sup>1,5</sup>, Alaina Bever<sup>1</sup>, Katherine L. Grantz<sup>1</sup>

<sup>1</sup>Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; <sup>2</sup>Department of Environmental Health, Rollins School of public Health, Emory University, Atlanta, GA; <sup>3</sup>School of Mathematical and Statistical Sciences, Clemson University, Clemson, SC; <sup>4</sup>The Prospective Group, Arlington, VA; <sup>5</sup>College of Health and Human Services, George Mason University, Fairfax, VA.

### Abstract

**Background:** Equivocal findings exist regarding prenatal acetaminophen use and various adverse neonatal and childhood health outcomes, though with no data on fetal growth. We evaluated whether fetal growth differed by maternal acetaminophen use.

**Methods:** Racially diverse, healthy women with low-risk antenatal profiles from 12 U.S. clinical centers were enrolled in a prospective cohort study and followed until delivery. Ultrasound measurements of fetal parameters and self-reported prenatal acetaminophen use were collected at enrollment and up to 5 follow-up visits. Prenatal acetaminophen use was dichotomized as none or any.

**Results:** Among 2,291 women, 932 (41%) reported the use of acetaminophen medications during the current pregnancy. Estimated growth curves of fetal parameters did not differ between women reporting use of any medication containing acetaminophen and women with no reported use of the same.

**Conclusion:** Among healthy mothers with low-risk pregnancies, maternal acetaminophen use was not associated with alterations in fetal growth.

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Address correspondence to: Melissa M. Smarr, 1518 Clifton Road NE, Atlanta, GA, 30322, melissa.smarr@emory.edu, Office: (404) 727-3809. Fax: (404) 727-8744.

Author Contributions:

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Dr. Smarr conceptualized and performed the analysis, drafted the initial manuscript, and reviewed and revised the manuscript.

Dr. Bible oversaw the statistical analysis, and critically reviewed the manuscript.

Dr. Gerlanc and Ms. Bever assisted with the imputation analysis, and critically reviewed the manuscript.

Drs. Buck Louis and Grantz conceptualized and designed the study, critically reviewed the manuscript.

**Conflict of Interest:** The authors have no conflicts of interest relevant to this article to disclose.

## Introduction

The use of non-prescription medications is generally considered safe for non-pregnant adults, which could explain the increase in use of over-the-counter (OTC) drugs during pregnancy. (1) Use of OTC medication occurs in an estimated 70% of pregnancies both nationally and internationally (2), and concerns about usage during pregnancy relative to fetal growth and development, in the absence of randomized clinical trials, remain.(3) One commonly used OTC analgesic and antipyretic, acetaminophen, also known as paracetamol outside of the United States and Canada, is found in a large number of OTC and prescription drugs.(4) Maternal intake of acetaminophen during pregnancy is believed to be non-toxic in low doses and was previously listed as a Pregnancy Category B drug according to the U.S. Food and Drug Administration.(3) The drug of choice for pain relief among most pregnant women, prenatal acetaminophen use has been reported in national and international epidemiologic studies with frequencies ranging from 29.9% to 81%.(5) Based on data from the National Birth Defect Prevention Study and the Boston University Slone Epidemiology Center Birth Defects Study, prevalence of acetaminophen use during any period of pregnancy is 65–70%; the highest prevalence was reported in the first trimester (54.2%), 50.5% in the second trimester and the lowest in the third trimester (48.0%).(1)

Given the high prevalence of acetaminophen use during pregnancy and the ability of acetaminophen to freely cross the placenta,(6, 7) researchers are now focusing on the safety of maternal exposure to acetaminophen and its effects on fetal health. Short- and long-term consequences of acetaminophen use during pregnancy are inconsistent for both animal and human studies.(8) Most of the previous literature is centered on acetaminophen use and observed birth defects in animal studies and increased odds of birth defects in human studies. In human studies, findings from a Danish prospective birth cohort study demonstrated that compared to mothers who reported no medication use, women who used paracetamol for more than two weeks during the first and second trimesters had increased risk of delivering boys with congenital cryptorchidism.(9) Other European studies have reported similar findings with significant associations between maternal acetaminophen use and male reproductive disorders, highlighting second trimester as a potential critical window of exposure.(10, 11)

Studies specific to fetal growth are limited and results are equivocal. Biologic plausibility stems from animal models, which have demonstrated that reduced fetal length in rat pups is associated with mid-gestation maternal exposure to 125 mg and 350 mg of acetaminophen, dosage comparable to maternal use. (12, 13) Various concentrations of acetaminophen have been associated with morphological changes in the fetal liver. It has been hypothesized that insults to the fetal liver may result in the reduction of blood stem cells to key organs, resulting in increased risk of adverse growth and development.(12) Epidemiologic studies of prenatal acetaminophen use and fetal growth are non-existent. Our objective was to compare growth curves of fetal parameters between maternal prenatal acetaminophen use groups in a prospective cohort of low-risk, ethnically and geographically diverse maternal-fetal pairs.

## Patients and Methods

### Study Sample

The NICHD Fetal Growth Study-Singletons was a multi-site, prospective cohort study designed to establish a standard for normal fetal growth (velocity) and size for gestational age for racially/ethnically diverse U.S. pregnant women. The study cohort comprised 2,334 non-obese (pregravid body mass index (BMI) 19.0–29.9 kg/m<sup>2</sup>) gravidas who were recruited from 12 clinical sites over the course of four years (2009–2013) with representation from four self-identified race/ethnicity groups: non-Hispanic black (n=611, 26%), Asian (n=460, 20%), non-Hispanic white (n=614, 26%), and Hispanic (n= 649, 28%). Inclusion and exclusion criteria were specified to recruit healthy women with low-risk antenatal profiles consistent with optimal fetal growth (14). As such, women with major risk factors for altered fetal growth (hypertension, smoking, maternal vascular disease etc.) were excluded from the study; full details of the study are provided elsewhere. (15)

Women were excluded from the current analysis if they did not meet the inclusion criteria after enrollment (n=14, <1%), did not have ultrasound data available from at least one study exam (n=8, <1%) or did not report any data on medication use (n=21, 1%). Institutional review board approval was obtained from all participating sites; women gave informed consent before data collection. **The NICHD Fetal Growth Studies Clinical Trial Registration:** [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00912132), NCT00912132.

### Covariate Data Collection & Self-reported Acetaminophen Use

Women were interviewed about lifestyle, medical, and reproductive history upon enrollment and at each of the subsequent five prenatal visits. Details surrounding medication use during pregnancy was self-reported and abstracted from enrollment, study visit and medical chart forms. During enrollment women were asked, “Since you became pregnant, have you used or taken any medications and nonprescription vitamins, minerals, herbals, and supplements?”, and at each study visit, women were asked, “Since your last visit with us, have you used or taken any medications and nonprescription vitamins, minerals, herbals, and supplements?” with a response option of yes, no, refused or don’t know. For a yes response, participants could provide detailed information for each reported product including medication name (free text), whether it was prescription or non-prescription, route (i.e. by mouth, etc.), frequency and duration of medication. At enrollment, women were asked “how often the medication was taken since pregnancy”, and at each follow-up visit, women were asked “how often do/did you take the product?”; (in addition to “refused” or “don’t know”, there were seven possible answers: “less than once a month”, “once a month”, “2–3 times a month (but less than once a week)”, “1–2 times a week”, “3–4 times a week”, “5–6 times a week” and “everyday”). Additionally, women were asked whether they were still taking the reported medication at enrollment and during each follow-up visit. After delivery, abstraction of the medical charts included the name of every medication including prescription, over the counter, and herbal medications, taken at any point during pregnancy along with the start date. Free text maternal medication data was mapped to drug categories in the Slone Drug Dictionary with the use of the Coding Engine program. The dictionary and coding program have been used in multiple studies of medication use. (16–18) The

Slone Drug Dictionary listed 1,177 acetaminophen-containing medications, of which a total of 24 unique medications were reported by women in our analytic cohort. Reported acetaminophen medications by active ingredients included: primarily acetaminophen (Acetaminophen, Paracetamol, Tylenol, Tylenol Extra Strength, and Children's Tylenol); acetaminophen plus Diphenhydramine HCl (Tylenol PM); acetaminophen plus cough and/or nasal suppressants (Tylenol Cold, Tylenol Sinus and Walgreens Cough Syrup); acetaminophen plus Aspirin (Excedrin and Excedrin Extra Strength); acetaminophen plus caffeine (Aspirin-Free Excedrin); acetaminophen plus hydrocodone (Lortab, Norco and Vicodin); acetaminophen plus oxycodone (Tylox and Percocet); acetaminophen plus codeine (Tylenol with codeine and Tylenol #3); acetaminophen plus butalbital (Fioricet and Phrenilin); acetaminophen plus propoxyphene (Darvocet); and acetaminophen plus isometheptene mucate, dichloralphenazone (Midrin).

### Assessment of Fetal Growth

Each woman was randomized to one of four follow-up schedules to capture ultrasound data across the full range of gestation while minimizing ultrasound exposure. As such, five additional ultrasounds were scheduled for each woman within  $\pm 1$  week of the targeted gestational age [baseline, visit 0: 8 to 13 weeks; visit 1: 16 to 22 weeks; visit 2: 24 to 29 weeks; visit 3: 30 to 33 weeks; visit 4: 34 to 37 weeks; and visit 5: 38 to 41 weeks]. (14) Fetal biometric measurements were performed at each visit according to standardized study procedures by study site sonographers who underwent credentialing that yielded excellent reliability for fetal measurements assessed via ultrasound examinations. (19) Ultrasound examination included biparietal diameter (BPD, outer to inner), head circumference (HC), abdominal circumference (AC), and femur length (FL), all measured to the nearest 0.1 millimeter (mm). For all biometric measurements, three measurements were taken and averaged. Estimated fetal weight (grams, g) was calculated from HC, AC and FL using the Hadlock formula. (20) Head/abdominal circumference (HC/AC) ratio was calculated to assess symmetry of fetal growth. (21) Femur length/abdominal circumference (FL/AC) ratio was calculated as an index to identify intrauterine growth restricted fetuses by indirectly detecting the degree of subcutaneous fat and muscle loss, independent of gestational age. (22) Study scans were captured using Voluson E8s (GE Healthcare, Milwaukee, WI) with a transabdominal curved multifrequency volume transducer (real-time abdominal 4–8 MHz) and / or endovaginal multifrequency volume transducer (real-time intracavity 6–12 MHz). Study scans underwent a quality assurance (QA) process, during which 5% of study scans with triplicate images for each fetal measurement were randomly selected to be re-measured by the expert sonographer (23). The QA demonstrated excellent ( $>0.90$ ) reliability of biometric measurements between study sonographers and blinded expert reviewers.

### Statistical Analysis

Maternal gestational use pattern for acetaminophen containing medications was dichotomized as no use or any use. These exposure categories were empirically selected given the potential for variable reporting of acetaminophen use. Maternal baseline characteristics were compared across gestational acetaminophen use groups using chi-square or Kruskal-Wallis tests for categorical or continuous data, respectively.

Longitudinal trajectories of each fetal parameter and EFW were estimated for each acetaminophen use group; curves were determined for the 10<sup>th</sup>, 50<sup>th</sup>, and 90<sup>th</sup> percentiles. Fetal biometric measurements and estimated fetal weight were log-transformed to normalize distributions. Using the Linear and Nonlinear Mixed Effects Models (nlme) R package, fetal parameter growth curves for each gestational acetaminophen use group were estimated from linear mixed models with cubic splines for gestational age with knots placed at the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles to evenly split the distributions. All mixed models included a random intercept and slope to account for the between and within-subject variability for each mother-fetal pair. We performed likelihood ratio tests for global differences in curves for each fetal parameter. When the global test was significant ( $\alpha=.05$ ), we performed pairwise comparisons for gestational week-specific differences of fetal parameter curves by categories of maternal acetaminophen use to assess significance using Wald p-values. Models were adjusted for maternal age, self-identified racial/ethnic group; type of insurance (private or managed care vs other); education (less than high school, high school or equivalent, some college or associate degree, bachelor degree and master or advanced degree); annual income (<\$30,000, \$30,000–39,999, \$40,000–49,999, \$50,000–74,999, \$75,000–99,999, \$100,000); and the number of jobs worked (none, one, two or more). The Multivariate Imputation by Chained Equations (MICE) software for R was used to impute missing covariates for a total of 10 replications ( $m=10$ ): highest level of education (< 1%), number of current paid jobs (< 1%), type of insurance (8%) and income during last year (15%), when performing adjusted tests for week-specific differences in fetal growth curves. Analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC) or R (version 3.3.0).

## Results

### Sample Characteristics

Among the 2,291 women (98%) included in the analysis, 932 (41%) reported the use of any medication containing acetaminophen during gestation. Of the prenatal acetaminophen users, 795 (85%) reported only using medications with acetaminophen as the sole active ingredient throughout follow-up. Another 89 women (9%), reported use of both medications with acetaminophen as the sole active ingredient and medications with other active ingredients (e.g., narcotics, antihistamines, nasal decongestants). An additional 54 women (6%) reported only using medications with a primary active ingredient other than acetaminophen (e.g. narcotics, antihistamines, nasal decongestants) but also containing acetaminophen.

The average maternal age at study enrollment was  $28.2 \pm 5.5$  years of age, and women generally had normal pregravid BMIs,  $23.6 \pm 3.0$  kg/m<sup>2</sup> as per study design (Table 1).. Compared with women who reported no acetaminophen use during their pregnancy, reported usage of acetaminophen was more prevalent among non-Hispanic White and non-Hispanic Black women ( $p<0.0001$ ). Additionally, having a college degree, an annual income \$100,000, having one or more jobs and having private insurance or managed care, was more prevalent among women with any reported acetaminophen use, compared with those reporting no use ( $p$ -values = 0.001, Table 1),.

## Estimates of Change in Growth of Fetal Biometry

Figure 1 presents the estimated curves of measured fetal parameters, BPD, HC, AC, and FL, by gestational acetaminophen use category, including the median (50<sup>th</sup>), 5<sup>th</sup> and 95<sup>th</sup> percentiles. We found no significant differences in estimated fetal parameters across gestation between reported acetaminophen use groups (all gestational week-specific global p-values  $\geq 0.05$ ). Estimated differences in fetal parameter means presented in Table 2, support the lack of variation between fetal growth parameters by reported prenatal acetaminophen use (pairwise comparison p-values  $\geq 0.05$ ).

The fetal curves (median, 5<sup>th</sup> and 95<sup>th</sup> percentiles) for estimated fetal parameters, EFW, HC/AC and FL/AC, by acetaminophen use category are displayed in Figure 2. Acetaminophen use patterns were not associated with differences in fetal EFW, HC/AC and FL/AC (gestational week-specific global  $P > 0.05$  for all).

## Discussion

In a prospective cohort of healthy pregnant women with low-risk antenatal profiles, prenatal acetaminophen use was not associated with fetal growth. These findings are reassuring given that use was common (41%) in our study population. Still, we exercise caution in our finding in light of our reliance on a rather global measure of self-reported usage that may not be sensitive to specific patterns of use. For example, most (n=495; 53%) women who reported using any acetaminophen medications noted intermittent use which may be associated with measurement error or bias.

It is difficult to compare our findings with previous epidemiologic studies, given the few population-based longitudinal studies currently addressing this question. Several earlier studies explored maternal use of acetaminophen during pregnancy and risk of allergic disorders (i.e. wheezing, asthma, eczema) in childhood (24–26) or neurodevelopment or behavioral outcomes (i.e. attention deficit hyperkinetic disorder). (27, 28) While some studies have reported increased odds ratio for amniotic band syndrome, with first trimester therapeutic use,(29) to our knowledge none has examined the relationship between prenatal acetaminophen use and growth of core fetal biometrics, estimated fetal weight or parameter ratios indicative of asymmetric fetal growth.

## Strengths and Limitations

The NICHD Fetal Growth Studies was an ambitious undertaking to define new fetal growth standards for racially/ethnically diverse pregnant women in light of marked demographic changes in contemporary pregnant women. The major strength of our study was the prospective collection of both medication use and fetal growth measurements at multiple study visits across gestation. Furthermore, women in the NICHD Fetal Growth Studies overwhelmingly reported free text medication data at every study visit. Moreover, the classification of such medication data according to the reputable Slone Drug Dictionary and ‘Coding Engine’ program, which identify medications according to a specific component, product, or group of products, limits potential exposure misclassification.



Potential limitations of this novel assessment include limited external validity or generalizability as our cohort, by design, was restricted to healthy women with low risk antenatal profiles. This may, in part, be reflected in the large percentage of women (59%) never reporting any prenatal acetaminophen use. We also recognize the potential limitations of assessing acetaminophen use with an open-ended questionnaire supplemented by chart review. There is the potential for under-reporting due to differences in recall or recognition of medications containing acetaminophen. Women in our cohort reporting acetaminophen use were more educated and had higher incomes than women with reported use. It remains possible that such women more reliably reported exposure or not if they had greater recognition of acetaminophen in other medications and reported it correctly. The extent to which such differences or other reporting biases may be generated with the use of self-administered questionnaires remains to be established. Another potential limitation is the lack of information on dosage provided by women in our cohort precluding a more formal investigation of potential dose response relationships. Furthermore, while data was collected on frequency of medication use since pregnancy was collected at enrollment and frequency of use since last visit was collected at each follow-up visit (Supplemental Table S1), the timing of follow-up is disjointed with the timing of exposure, meaning that we only know that exposure occurred sometime between the prior and current visits. The unknown timing (date of acetaminophen use) of exposure coupled with the sparse exposure patterns make modeling of growth trajectories as a function of temporally varying exposure (acetaminophen use) a non-trivial task. However, if we had coarsened the timing of use (i.e., trimesters) the exposure data would have resulted in sparse acetaminophen use patterns, which would have made the identification of distinct growth trajectories for each use profile unrealistic (Supplemental Table S2). Finally, we were unable to adjust for confounding by indication as not all women provided information on why they were taking medications containing acetaminophen.

## Conclusions

Among healthy pregnant women, we found no evidence to support that maternal acetaminophen use was associated with altered fetal growth. With the recent attention placed on acetaminophen use and the potential for the Food and Drug Administration to re-evaluate the classification of medications containing this drug and their use during pregnancy<sup>30</sup>, our findings may offer reassurance to mothers who have limited medication options and require pain or fever relief. Still, other important neonatal outcomes await purposeful investigation to ensure the absence of developmental toxicity.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We would like to acknowledge the research teams at all participating clinical centers, including Christina Care Health Systems; University of California, Irvine; Long Beach Memorial Medical Center; Northwestern University; Medical University of South Carolina; Columbia University; New York Hospital Queens; St. Peters' University Hospital; University of Alabama at Birmingham; Women and Infants Hospital of Rhode Island; Fountain Valley Regional Hospital and Medical Center; and Tufts University. Additionally, we acknowledge GE Healthcare

Women's Health Ultrasound for their support and training on the Voluson and ViewPoint products over the course of this study, along with C-TASC and the EMMES Corporation for providing data and imaging support for this multisite study.


**Funding/Support:** This work was supported by the Intramural Research Program of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, contracts HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C.

## References

1. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA 2005 Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol* 193:771–777. [PubMed: 16150273]
2. Lupattelli A, Spigset O, Twigg MJ, et al. 2014 Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open* 4.
3. Servey J, Chang J 2014 Over-the-Counter Medications in Pregnancy. *American Academy of Family Physicians* 90:548–555.
4. Lank P 2014 Acetaminophen. *American College of Medical Toxicology*.
5. Modick H, Weiss T, Dierkes G, Bruning T, Koch HM 2014 Ubiquitous presence of paracetamol in human urine: sources and implications. *Reproduction* 147:R105–117. [PubMed: 24451225]
6. Byer AJ, Traylor TR, Semmer JR 1982 Acetaminophen overdose in the third trimester of pregnancy. *Jama* 247:3114–3115. [PubMed: 7077806]
7. Arcangelo VP, Peterson AM 2006 Principles of Pharmacotherapy in Pregnancy and Lactation In Gaber S (ed) *Pharmacotherapeutics for Advanced Practice: A Practical Approach*. Lippincott Williams & Wilkins.
8. Thiele K, Kessler T, Arck P, Erhardt A, Tiegs G 2013 Acetaminophen and pregnancy: short- and long-term consequences for mother and child. *J Reprod Immunol* 97:128–139. [PubMed: 23432879]
9. Kristensen DM, Hass U, Lesne L, et al. H 2011 Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Hum Reprod* 26:235–244. [PubMed: 21059752]
10. Jensen MS, Rebordosa C, Thulstrup AM, et al. 2010 Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology* 21:779–785. [PubMed: 20805751]
11. Philippat C, Giorgis-Allemand L, Chevrier C, et al. 2011 Analgesics during pregnancy and undescended testis. *Epidemiology* 22:747–749. [PubMed: 21811116]
12. Burdan F, Siezieniewska Z, Kis G, Blicharski T 2001 Embryofetotoxicity of acetaminophen (paracetamol) in experimental in vivo model. *Ann Univ Mariae Curie Sklodowska Med* 56:89–94. [PubMed: 11977371]
13. Lubawy WC, Garrett RJ 1977 Effects of aspirin and acetaminophen on fetal and placental growth in rats. *J Pharm Sci* 66:111–113. [PubMed: 833724]
14. Buck Louis GM, Grewal J, Albert PS, et al. 2015 Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. *Am J Obstet Gynecol* 213:449.e441–449.e441. [PubMed: 26410205]
15. Grewal J, Grantz KL, Zhang C, et al. 2017 Cohort Profile: NICHD Fetal Growth Studies—Singletons and Twins. *International Journal of Epidemiology*:dyx161-dyx161.
16. Hall SA, Chiu GR, Kaufman DW, et al. 2010 General exposures to prescription medications by race/ethnicity in a population-based sample: Results from the Boston Area Community Health Survey. *Pharmacoepidemiology and drug safety* 19:384–392. [PubMed: 20140890]
17. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. *American Journal of Obstetrics & Gynecology* 204:314.e311–314.e311.
18. Benedum CM, Yazdy MM, Mitchell AA, Werler MM 2015 Impact of Periconceptional Use of Nitrosatable Drugs on the Risk of Neural Tube Defects. *American Journal of Epidemiology*.
19. American Institute of Ultrasound Medicine. 2010 AIUM practice guideline for the performance of obstetric ultrasound examinations. *J Ultrasound Med* 29:9.




20. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK 1985 Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study. *Am J Obstet Gynecol* 151:333–337. [PubMed: 3881966]
21. Peleg D, Kennedy CM, Hunter SK 1998 Intrauterine growth restriction: identification and management. *Am Fam Physician* 58:453–460, 466–457. [PubMed: 9713399]
22. Bamberg C, Kalache KD 2004 Prenatal diagnosis of fetal growth restriction. *Semin Fetal Neonatal Med* 9:387–394. [PubMed: 15691774]
23. Hediger ML, Fuchs KM, Grantz KL, et al. 2016 Ultrasound Quality Assurance for Singletons in the National Institute of Child Health and Human Development Fetal Growth Studies. *J Ultrasound Med* 35:1725–1733. [PubMed: 27353072]
24. Shaheen SO, Newson RB, Henderson AJ, et al. S 2005 Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. *Clin Exp Allergy* 35:18–25. [PubMed: 15649261]
25. Persky V, Piorkowski J, Hernandez E, et al. 2008 Prenatal exposure to acetaminophen and respiratory symptoms in the first year of life. *Ann Allergy Asthma Immunol* 101:271–278. [PubMed: 18814450]
26. Garcia-Marcos L, Sanchez-Solis M, Perez-Fernandez V 2011 Early exposure to acetaminophen and allergic disorders. *Curr Opin Allergy Clin Immunol* 11:162–173. [PubMed: 21505328]
27. Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J 2014 Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. *JAMA Pediatr* 168:313–320. [PubMed: 24566677]
28. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H 2013 Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. *Int J Epidemiol* 42:1702–1713. [PubMed: 24163279]
29. Werler MM, Louik C, Mitchell AA 2003 Epidemiologic analysis of maternal factors and amniotic band defects. *Birth Defects Res A Clin Mol Teratol* 67:68–72. [PubMed: 12749386]



**Figure 1. Trajectories for measured fetal parameters by maternal acetaminophen use categories, NICHD Fetal Growth Studies - Singletons.**

Estimated 5th, 50th, and 95th percentiles for fetal biparietal diameter (a), head circumference (b), abdominal circumference (c) and femur length (d) by maternal self-reported prenatal acetaminophen use categories, as estimated from linear mixed models with log-transformed outcomes and cubic splines. mm, millimeters.



**Figure 2. Trajectories for derived fetal parameters by maternal acetaminophen use categories, NICHD Fetal Growth Studies - Singletons.**

Estimated 5th, 50th, and 95th percentiles for fetal estimated fetal weight (a), head circumference to abdominal circumference ratio (b), and femur length to abdominal circumference (c) by maternal self-reported prenatal acetaminophen use categories, as estimated from linear mixed models with log-transformed outcomes and cubic splines. g, grams.

**Table 1.**

Comparison of analytic cohort characteristics by prenatal acetaminophen use categories.

Characteristic	Overall (N=2291)	No reported use (n= 1359)	Any reported use (n = 932)	p-value
	n (%) <sup>a</sup>	n (%) <sup>a</sup>	n (%) <sup>a</sup>	
Age, Maternal (years): Mean (SD)	28.2 (5.5)	28.1 (5.5)	28.4 (5.5)	0.15
Pregravid BMI (kg/m2): Mean (SD)	23.6 (3.0)	23.5 (3.0)	23.8 (3.0)	0.02
Education:				<0.0001
Less than high school	245 (10.7)	178 (13.1)	67 (7.2)	
High school diploma or GED or equivalent	394 (17.2)	243 (17.9)	151 (16.2)	
Some college or Associate degree	671 (29.3)	409(30.1)	262 (28.1)	
Bachelor's degree	557 (24.3)	309 (22.7)	248 (26.6)	
Master's degree or Advanced degree	424 (18.5)	220 (16.2)	204 (21.9)	
Race:				<0.0001
Non-Hispanic White	605 (26.4)	275 (20.2)	330 (35.4)	
Non-Hispanic Black	593 (25.9)	304 (22.4)	289 (31.0)	
Hispanic	639 (27.9)	443 (32.6)	196 (21.0)	
Asian & Pacific Islander	454(19.8)	337 (24.8)	117 (12.6)	
Income:				<0.0001
Less than \$30,000	543 (27.8)	350 (31.3)	193 (23.1)	
\$30,000-\$39,999	180 (9.2)	116 (10.4)	64 (7.7)	
\$40,000-\$49,999	156 (8.0)	101 (9.0)	55 (6.6)	
\$50,000-\$74,999	239 (12.2)	136 (12.1)	103 (12.3)	
\$75,000-\$99,999	263 (13.4)	140 (12.5)	123 (14.7)	
\$100,000 or more	575 (29.4)	277 (24.7)	298 (35.6)	
Number of jobs:				<0.0001
None	792 (34.6)	516 (38.0)	276 (29.6)	
One job	1398 (61.0)	798 (58.7)	600 (64.4)	
Two or more jobs	101 (4.4)	45 (3.3)	56 (6.0)	
Insurance:				0.0005
Other	755 (35.4)	480 (38.4)	275 (31.1)	
Private or Managed Care	1380 (64.6)	771 (61.6)	609 (68.9)	
Sex:				0.52
Male	1103 (52.2)	652 (52.8)	451 (51.4)	
Female	1010 (47.8)	583 (47.2)	427 (48.6)	

<sup>a</sup>Values are presented as n (%) unless noted as mean (SD).

Reported p-values are for Kruskal-Wallis tests for continuous variables or Chi-square tests for categorical variables comparisons between women with no and any prenatal acetaminophen use.

**Table 2.**

Fetal parameter differences and pairwise p-values between maternal prenatal acetaminophen use by gestational weeks, NICHD Fetal Growth Studies.

Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
Abdominal Circumference (mm)	10	1.2	0.05
	11	1.05	0.05
	12	0.86	0.11
	13	0.65	0.26
	14	0.47	0.46
	15	0.35	0.63
	16	0.3	0.76
	17	0.32	0.81
	18	0.39	0.81
	19	0.49	0.76
	20	0.61	0.7
	21	0.74	0.64
	22	0.88	0.58
	23	1.03	0.53
	24	1.18	0.48
	25	1.33	0.43
	26	1.48	0.4
	27	1.63	0.37
	28	1.76	0.35
	29	1.88	0.35
	30	1.98	0.36
	31	2.07	0.38
	32	2.14	0.4
	33	2.2	0.43
	34	2.25	0.44
	35	2.3	0.44
	36	2.37	0.44
	37	2.5	0.45
	38	2.73	0.47
	39	3.11	0.53
	40	3.67	0.68
Biparietal Diameter (mm)	10	0.47	0.63
	11	0.32	0.97
	12	0.15	0.54
	13	0	0.31
	14	-0.1	0.21

Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
	15	-0.13	0.19
	16	-0.1	0.21
	17	-0.01	0.29
	18	0.1	0.45
	19	0.21	0.68
	20	0.29	0.85
	21	0.35	0.94
	22	0.39	0.95
	23	0.41	0.9
	24	0.4	0.81
	25	0.38	0.7
	26	0.35	0.6
	27	0.31	0.51
	28	0.27	0.46
	29	0.25	0.44
	30	0.23	0.43
	31	0.23	0.45
	32	0.24	0.46
	33	0.24	0.45
	34	0.24	0.41
Femur Length (mm)	35	0.22	0.35
	36	0.19	0.29
	37	0.14	0.25
	38	0.09	0.24
	39	0.02	0.28
	40	-0.06	0.45
	10	-0.05	0.28
	11	0.01	0.99
	12	0.11	0.22
	13	0.24	0.08
	14	0.37	0.09
	15	0.47	0.19
16	0.52	0.45	
17	0.52	0.81	
18	0.49	0.98	
19	0.45	0.99	
20	0.43	0.93	
21	0.43	0.86	
22	0.44	0.79	



Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
	23	0.47	0.73
	24	0.51	0.68
	25	0.56	0.65
	26	0.61	0.65
	27	0.65	0.68
	28	0.69	0.75
	29	0.7	0.86
	30	0.68	0.98
	31	0.65	0.84
	32	0.62	0.74
	33	0.6	0.71
	34	0.61	0.78
	35	0.66	0.98
	36	0.74	0.81
	37	0.83	0.75
	38	0.9	0.97
	39	0.94	0.45
	40	0.89	0.11
Head Circumference (mm)	10	0.8	0.38
	11	0.68	0.54
	12	0.53	0.74
	13	0.4	0.84
	14	0.31	0.83
	15	0.28	0.75
	16	0.31	0.64
	17	0.39	0.57
	18	0.51	0.59
	19	0.63	0.69
	20	0.75	0.76
	21	0.86	0.81
	22	0.95	0.83
	23	1.04	0.83
	24	1.1	0.82
	25	1.15	0.79
	26	1.18	0.75
	27	1.19	0.71
28	1.18	0.67	
29	1.16	0.63	
30	1.12	0.59	

Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
	31	1.07	0.56
	32	1.03	0.53
	33	0.99	0.51
	34	0.96	0.49
	35	0.96	0.48
	36	0.96	0.49
	37	0.95	0.5
	38	0.88	0.5
	39	0.72	0.5
	40	0.45	0.55
Estimated Fetal Weight (g)	10	0.46	0.54
	11	0.67	0.63
	12	0.92	0.74
	13	1.20	0.8
	14	1.54	0.83
	15	1.93	0.82
	16	2.39	0.79
	17	2.96	0.77
	18	3.68	0.77
	19	4.64	0.78
	20	5.91	0.76
	21	7.55	0.7
	22	9.61	0.62
	23	12.14	0.54
	24	15.13	0.46
	25	18.59	0.39
	26	22.44	0.33
	27	26.57	0.3
	28	30.81	0.29
	29	34.90	0.3
	30	38.70	0.34
	31	42.27	0.4
	32	45.77	0.47
	33	49.49	0.54
	34	53.89	0.57
	35	59.50	0.58
	36	66.07	0.55
	37	72.63	0.53
38	77.88	0.54	

Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
	39	80.24	0.6
	40	77.83	0.75
HC/AC	10	-0.01	0.11
	11	-0.01	0.44
	12	-0.01	0.77
	13	-0.01	0.33
	14	0.00	0.27
	15	0.00	0.36
	16	0.00	0.55
	17	0.00	0.8
	18	0.00	0.93
	19	0.00	0.91
	20	0.00	0.89
	21	0.00	0.88
	22	0.00	0.89
	23	0.00	0.92
	24	0.00	0.97
	25	0.00	0.98
	26	0.00	0.91
	27	0.00	0.84
	28	0.00	0.76
	29	0.00	0.67
	30	0.00	0.59
	31	0.00	0.54
	32	0.00	0.52
	33	0.00	0.53
	34	0.00	0.58
	35	0.00	0.7
	36	0.00	0.82
	37	0.00	0.87
38	0.00	0.78	
39	-0.01	0.51	
40	-0.01	0.3	
FL/AC	10	0.00	0.06
	11	0.00	0.03
	12	0.00	0.05
	13	0.00	0.1
	14	0.00	0.19
	15	0.00	0.27

Fetal parameter	Gestational Age (weeks)	Difference: Use vs No Use	p-value <sup>b</sup>
	16	0.00	0.33
	17	0.00	0.39
	18	0.00	0.45
	19	0.00	0.5
	20	0.00	0.51
	21	0.00	0.48
	22	0.00	0.42
	23	0.00	0.34
	24	0.00	0.27
	25	0.00	0.2
	26	0.00	0.16
	27	0.00	0.12
	28	0.00	0.1
	29	0.00	0.08
	30	0.00	0.08
	31	0.00	0.09
	32	0.00	0.1
	33	0.00	0.11
	34	0.00	0.12
	35	0.00	0.12
	36	0.00	0.12
	37	0.00	0.13
	38	0.00	0.13
	39	0.00	0.16
	40	0.00	0.29

Abbreviations: HC/AC head circumference to abdominal circumference ratio; FL/AC, femur length to abdominal circumference ratio.

<sup>a</sup> p-values obtained by Wald test with adjustment for maternal age, self-identified racial/ethnic group; type of insurance (private or managed care vs other); education (less than high school, high school or equivalent, some college or associate degree, bachelor degree and master or advanced degree); annual income (<\$30,000, \$30,000–39,999, \$40,000–49,999, \$50,000–74,999, \$75,000–99,999, \$100,000); and the number of jobs worked (none, one, two or more).